TOPLINE

A network meta-analysis of randomized controlled trials found that dexmedetomidine use may reduce the risk for postoperative delirium compared with normal saline in adult patients who were treated in the ICU following noncardiac surgery. However, dexmedetomidine probably raises the risk for bradycardia relative to propofol.

METHODOLOGY

• Researchers conducted a systematic review and network meta-analysis of randomized controlled trials that compared the effects of dexmedetomidine vs other sedatives or normal saline among adults in the ICU after noncardiac surgery.
• The systematic review included 24 randomized controlled trials (2777 patients), 22 of which (2544 patients) were included in the network meta-analysis. 
• The primary outcome assessed was the incidence of delirium during the stay in the ICU.
• Secondary outcomes were length of stay in the ICU, time to extubation, bradycardia, hypotension, and duration of mechanical ventilation.
• Relative risks (RRs) and mean differences were reported, with intervention rankings determined via surface under the cumulative ranking curve (SUCRA).

TAKEAWAY

• Dexmedetomidine was associated with a lower risk for delirium compared with normal saline (RR, 0.46; 95% CI, 0.36-0.59; low certainty; six studies) and midazolam (RR, 0.11; 95% CI, 0.02-0.80; very low certainty; one study).
• Dexmedetomidine probably elevated the risk for bradycardia vs propofol (RR, 3.03; 95% CI, 1.39-6.25; low certainty). Compared with midazolam, dexmedetomidine probably shortened time to extubation (mean difference, -0.28 days; 95% CI, -0.41 to -0.15; moderate certainty; I² = 95%).
• The evidence was insufficient to establish whether the risk for delirium differed between dexmedetomidine and propofol or whether dexmedetomidine affected duration of mechanical ventilation, risk for hypotension, or length of stay in ICU compared with any of the evaluated sedative strategies.
• Across sedative strategies, dexmedetomidine achieved the highest ranking in delirium prevention (SUCRA, 0.97), whereas midazolam scored poorest (SUCRA, 0.08). Regarding bradycardia, dexmedetomidine had the lowest ranking (SUCRA, 0.03), whereas midazolam and propofol had the most favorable rankings (SUCRA, 0.83 and 0.77, respectively).

IN PRACTICE

"Dexmedetomidine may be preferentially considered for postoperative ICU patients at higher risk of delirium, particularly when preservation of neurocognitive function is a clinical priority. However, sedative selection should not be viewed as a standalone intervention capable of substantially altering major postoperative or ICU outcomes across heterogeneous populations," the researchers wrote. "Its use, therefore, requires careful patient selection and vigilant monitoring for bradycardia, with attention to dosing strategies that minimise cardiovascular adverse effects," they added.

SOURCE

The study was led by Christina Chae Yon Shin, MD, BMed, of the Department of Intensive Care Medicine at Fairfield Hospital in Sydney, Australia. It was published online on October 2 in Anaesthesia Critical Care & Pain Medicine.

LIMITATIONS

The certainty of evidence ranged from low to very low for multiple outcomes, attributed to limited sample sizes, substantial heterogeneity among studies, and a lack of precision. Trials examined dexmedetomidine across varied clinical contexts, including low-dose prophylactic therapy for the prevention of delirium and deep sedation among patients who were intubated, which could have affected the effects specific to each context and the interpretation.

DISCLOSURES

No specific funding information or conflicts of interest were reported.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.